Literature DB >> 7915248

Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGM1)".

R A Kroczek1, D Graf, D Brugnoni, S Giliani, U Korthüer, A Ugazio, G Senger, H W Mages, A Villa, L D Notarangelo.   

Abstract

X-linked immunodeficiency with hyper-IgM (HIGM1) is a rare disorder, characterized by recurrent infections associated with very low or absent IgG and IgA, and normal to increased IgM serum levels. The disease has been earlier mapped to the q26-27 region of the X-chromosome. We have identified a novel molecule expressed on the surface of activated T cells, which was designated TRAP (Tumor necrosis factor Related Activation Protein), and could demonstrate that TRAP is a ligand for the CD40 receptor expressed on B cells. Our mapping of the TRAP gene to the Xq26.3-27.1 region suggested a causal relationship to HIGM1. Further work revealed that various mutations of the TRAP/CD40 ligand (CD40L) gene may lead to a defective expression of the TRAP/CD40L molecule on the T-cell surface in HIGM1 patients. A combination of structural and functional analyses finally demonstrated that the failure of TRAP/CD40L on T cells to interact with CD40 on B cells is responsible for the inefficient T-cell help for B cells observed in HIGM1. The observations made in HIGM1 allowed us to conclude that TRAP/CD40L is not required for IgM synthesis. In contrast, functional expression of TRAP is a prerequisite for effective immunoglobulin isotype switching and subsequent production of IgG, IgA and IgE by B cells in vivo. The interaction of TRAP/CD40L with CD40 thus provides a very critical link between the cellular and the humoral part of the immune system. The knowledge of TRAP/CD40L cDNA sequence, the availability of various reagents for the testing of expression and function of TRAP/CD40L, and our recent elucidation of the exon-intron structure of the TRAP/CD40L gene now provide all necessary tools for early diagnosis of affected patients and the detection of female carriers of HIGM1. The available information will also provide a basis for future attempts at gene therapy in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915248     DOI: 10.1111/j.1600-065x.1994.tb00846.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  31 in total

1.  A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.

Authors:  B Barnhart; G S Ford; A Bhushan; C Song; L R Covey
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

3.  Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Authors:  Cécile Contin; Vincent Pitard; Yahsou Delmas; Nadège Pelletier; Thierry Defrance; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 4.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

5.  CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.

Authors:  R S Kornbluth; K Kee; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  Thymic B cells of pig fetuses and germ-free pigs spontaneously produce IgM, IgG and IgA: detection by ELISPOT method.

Authors:  B Cukrowska; J Sinkora; L Mandel; I Splíchal; A T Bianchi; F Kovárů; H Tlaskalová-Hogenová
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

7.  Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM.

Authors:  K C Gilmour; D Walshe; S Heath; G Monaghan; S Loughlin; T Lester; G Norbury; C M Cale
Journal:  Mol Pathol       Date:  2003-10

8.  Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice.

Authors:  Lili Chen; Wen Cheng; Pooja Shivshankar; Lei Lei; Xiaoyun Zhang; Yimou Wu; I-Tien Yeh; Guangming Zhong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

Review 9.  [Classification and diagnosis of immunodeficiency syndromes].

Authors:  K Warnatz; H-H Peter
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

10.  Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells.

Authors:  Geneviève Martin; Jocelyn Roy; Corinne Barat; Michel Ouellet; Caroline Gilbert; Michel J Tremblay
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.